Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 63.00
Bid: 61.00
Ask: 65.00
Change: 0.00 (0.00%)
Spread: 4.00 (6.557%)
Open: 63.00
High: 63.00
Low: 63.00
Prev. Close: 63.00
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wanda Technology Enhancements

18 Jul 2018 07:00

RNS Number : 9050U
NetScientific PLC
18 July 2018
 

 

 

NetScientific plc

("NetScientific" or the "Company" or the "Group")

 

Portfolio Company, Wanda Enhances Remote Patient Monitoring Platform with Improved Patient Adherence Features

 

London, UK - July 18th, 2018 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that portfolio company Wanda, which uses machine learning to help healthcare providers to better manage the risk and care of patients, has completed a significant enhancement of its Patient Management Platform to improve patient adherence to care plans. Use of Wanda's existing platform had been shown to predict 90% of patient-level adverse events up to 7 days in advance of their occurrence, and allows for virtual intervention to prevent such events.

 

The new enhanced Patient Reminder Suite empowers clinicians to better engage patients in care plan adherence through personalised reminders and alerts, which can be pre-scheduled and delivered via multi-modal communications. The enhancements also include the adoption of the Cloud Text-to-Speech Application Programming Interface from Google that uses machine learning to deliver natural-sounding human voice automation. The combined effect of the enhanced reminder tools, the early prediction of adverse events, and the virtual intervention insight gives providers a highly intelligent method to defend against the costs of unplanned readmissions and emergency department visits due to nonadherence.

 

Commenting on the news, Francois R. Martelet, NetScientific's Chief Executive Officer and Chairman of Wanda, said: "Wanda's enhancements to its core technology mean that relationships between clinicians and patients will continue to improve, and will empower patients to take a more active role in the management of their diseases as well as increase their quality of life. We continue to see invaluable potential in Wanda and look forward to monitoring its progress in the coming months."

 

NetScientific holds a 62% stake on a fully diluted basis in Wanda.

 

For more information, please contact:

 

  NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO

Tel: +44 (0)20 3514 1800

Wanda, Inc.

Bill Basset, CCO

Tel: +1 (0)206 910 0428

 

Consilium Strategic Communications

Mary-Jane Elliott / Chris Welsh / Laura Thornton

 

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

Stifel Nicolaus Europe Limited (NOMAD and Broker)

Jonathan Senior / David Arch / Ben Maddison

 Tel: +44 (0) 20 7710 7600

 

 

About NetScientific

 

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

 

 

Wanda Expands Patient Management Platform with Enhanced Patient Adherence Features

San Francisco, CA - July 18th, 2018 - Wanda, Inc. announces a significant expansion of their market-leading Patient Management Platform with expansive new features to further improve patient care plan adherence. The Wanda solution, embedded with clinically proven machine learning, predicts 90% of patient-level adverse events seven days before they occur and then facilitates virtual interventions to keep them from occurring. The enhanced Patient Reminder Suite empowers clinicians to better engage patients in care plan adherence through personalized reminders and alerts, which can be pre-scheduled and delivered via multi-modal communications. The enhancements also include the adoption of the Cloud Text-to-Speech API from Google that uses machine learning to deliver natural-sounding human voice automation.

The combined effect of the enhanced reminder tools, the early prediction of adverse events, and the virtual intervention insight gives providers a highly intelligent method to defend against the costs of unplanned readmissions and emergency department visits due to nonadherence. Depending on the complexity of the care plan, as many as 40% of patients fail to adhere to treatment plans.1 Between $100 and $300 billion in avoidable health care costs have been attributed to non-adherence in the US annually, representing 3%-10% of total US healthcare costs.2

"Healthcare providers have been pleased with how the Wanda platform has positively impacted the relationship between patients and their clinical care teams. The clinicians are able better deliver on their mission to provide great care with meaning and timely insight. Patients are more engaged and in control of the care", stated William Bassett, Chief Commercialization Officer of Wanda, Inc.

A key driver in patient non-adherence is related to medications with adherence rates dropping to 20% for patients that are required to take thirteen or more medications per day.3 Patient non-adherence can be corrected by the patient with the appropriate support. The leading reason for non-adherence most commonly reported was forgetfulness by the patient.4 The Patient Reminder Suite in Wands is specifically designed help clinicians easily create, personalize, and schedule reminders for all types of care support needs including medication reminders, vitals, daily symptom survey questions, pending visits to the doctor or at home visits, and prompts to exercise. For patients that prefer to interact with Wanda using the interactive voice response model, the inclusion of the Google voice technology provides a warm sounding human voice adding even more satisfaction to the patient interaction.

"Wanda continues to expand on its mission to fuse cutting edge data science with clinical care management to solve the major roadblocks in care models," said Ahsan Samiee, Chief Technology Officer, Wanda, Inc. "The financial and clinical results achieved by customers continue to validate our belief that these approaches should be imbued across healthcare for the betterment of all."

 

1, 3. Martin L, Williams S, Haskard, DiMatteo M. 2005. The Challenge of Patient Adherence. Therapeutics and Clinical Risk Management. 2005; 189-199.

2, 4. Iuga A, McGuire M. 2014. Adherence and Health Care Costs. Risk Management and Healthcare Policy. 2104; 35-44.

 

About Wanda, Inc.

Wanda is dedicated to advancing the effectiveness and efficiency of medicine by using machine learning and modern software applications that empower payers and providers to better manage the risk and care of patients dramatically lowering the cost of care and improving outcomes. More information about Wanda can be found at http://www.yourwanda.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABBGDRRGBBGIR
Date   Source Headline
15th Apr 20247:00 amRNSProAxsis secures c.£1.8mn investment
27th Mar 20241:34 pmRNSPDS Strategy Update and 2023 Financial Results
13th Mar 20247:00 amRNSBusiness Update
5th Feb 20247:00 amRNSExercise of Options and Issue of Shares
23rd Jan 20247:00 amRNSGlycotest secures $1 million investment
1st Dec 20237:00 amRNSDeepTech Recycling secures £1 million investment
14th Nov 20234:39 pmRNSPDS BioTechnology: Third Quarter Results
13th Nov 20237:00 amRNSDirector/PDMR Shareholding
9th Nov 20235:28 pmRNSPDS Biotech Announces Updated Survival Data
6th Nov 20237:00 amRNSVentive secures c.£900,000 investment
2nd Nov 20237:00 amRNSChange of Adviser
23rd Oct 20236:22 pmRNSPDS Preliminary Biomarker Study Results
13th Oct 20237:00 amRNSExercise of Options
3rd Oct 20234:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20233:21 pmRNSPDS: Interim 24-month survival rate of 74% update
3rd Oct 20237:00 amRNSPDS Biotech: new data on PDS0101
28th Sep 20237:00 amRNSInterim Results
13th Sep 20237:00 amRNSQ-Bot: £3.5 million investment to drive expansion
14th Aug 20235:55 pmRNSPDS Biotech: 2nd Quarter Results, Business Update
14th Aug 20235:51 pmRNSPDS Biotech: Submission of Phase 3 Protocol to FDA
3rd Jul 20237:00 amRNSGrant of Options, Issue of Shares, Director/PDMR
30th Jun 20237:00 amRNSDName-iT Holdings Limited Fundraising
29th Jun 202311:04 amRNSResult of AGM & Board Changes
22nd Jun 20237:00 amRNSVortex Fundraising
14th Jun 20233:31 pmRNSPDS Announces Achievement of Efficacy Threshold
7th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSNotice of AGM
31st May 20237:01 amRNSPreliminary Results for the year ended 31 Dec 2022
31st May 20237:00 amRNSBoard Changes
26th May 20239:39 amRNSPDS Biotech Announces Interim Data
24th May 20237:00 amRNSSofant and Inmarsat announce joint development
15th May 20233:16 pmRNSPDS Business Update and First Quarter Results
2nd May 20237:00 amRNSGlycotest, Inc. Fundraising
3rd Apr 20237:00 amRNSBusiness Update
30th Mar 20233:51 pmRNSPDS Update
28th Mar 20233:50 pmRNSPDS Business Update and 2022 Financial Results
28th Feb 20237:00 amRNSRelated party loan to ProAxsis Limited
27th Feb 20233:28 pmRNSPDS completes FDA meeting for triple combination
10th Feb 20232:05 pmRNSSecond Price Monitoring Extn
10th Feb 20232:00 pmRNSPrice Monitoring Extension
10th Feb 202311:05 amRNSSecond Price Monitoring Extn
10th Feb 202311:00 amRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSBoard Change
3rd Jan 20231:31 pmRNSPDS Announces Exclusive Global License Agreement
28th Dec 20223:05 pmRNSPDS Biotech: Median Overall Survival announcement
16th Dec 20227:00 amRNSPDS: HPV16 Head and Neck Cancer announcement
12th Dec 20222:00 pmRNSBoard Changes; Options; Co-Investment Agreement
29th Nov 20227:00 amRNSEMV C leads £4.2m round in 5G and SATCOM leader
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update
14th Nov 20222:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.